BioIndustry Ethics
Autor David L. Finegold, Cecile M Bensimon, Abdallah S. Daar, Margaret L. Eaton, Beatrice Godard, Bartha Maria Knoppers, Jocelyn Mackie, Peter A. Singeren Limba Engleză Paperback – 18 iul 2005
Preț: 427.73 lei
Nou
Puncte Express: 642
Preț estimativ în valută:
81.85€ • 86.11$ • 67.77£
81.85€ • 86.11$ • 67.77£
Carte tipărită la comandă
Livrare economică 14-28 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780123693709
ISBN-10: 0123693705
Pagini: 384
Dimensiuni: 152 x 229 x 25 mm
Greutate: 0.61 kg
Editura: ELSEVIER SCIENCE
ISBN-10: 0123693705
Pagini: 384
Dimensiuni: 152 x 229 x 25 mm
Greutate: 0.61 kg
Editura: ELSEVIER SCIENCE
Public țintă
Advanced undergraduate and graduate students in courses focusing on biotechnology in business, law medicine, biology and public health; Managers and employees in biotech and pharmaceutical companies as well as venture capitalists and financial analystsCuprins
Chapter
1:
INTRODUCTION
Chapter 2: MERCK: STAYING THE COURSE
Chapter 3: GENZYME: PUTTING PATIENTS FIRST
Chapter 4: MILLENNIUM PHARMACEUTICALS, INC.: CREATING AND SUSTAINING CORPORATE VALUES
Chapter 5: MAXIM PHARMACEUTICALS (A): INTERNAL AND EXTERNAL DIALOGUES
Chapter 6: DIVERSA INC.: ETHICAL ISSUES IN BIOPROSPECTING PARTNERSHIPS
Chapter 7: PIPELINE BIOTECH A/S: COMPETING REGULATORY REGIMES FOR LABORATORY ANIMAL EXPERIMENTS
Chapter 8: TGN BIOTECH: A START-UP WITH ETHICAL ROOTS
Chapter 9: INTERLEUKIN GENETICS AND ALTICOR: AN UNLIKELY PARTNERSHIP
Chapter 10: SCIONA LTD.: A PIONEER IN NUTRIGENOMICS: THE PATH TO CONSUMER ACCEPTANCE
Chapter 11: AFFYMETRIX, INC.: USING CORPORATE ETHICS ADVICE
Chapter 12: PHARMASNPS INC.: CREATING AN ETHICS ADVISORY BOARD
Chapter 13: MONSANTO COMPANY: BIO-AGRICULTURE PIONEER
Chapter 14: NOVO NORDISK: THE TRIPLE BOTTOM LINE
Chapter 15: CONCLUSION: LESSONS FOR COMPANIES AND FUTURE ISSUES
INDEX
Chapter 2: MERCK: STAYING THE COURSE
Chapter 3: GENZYME: PUTTING PATIENTS FIRST
Chapter 4: MILLENNIUM PHARMACEUTICALS, INC.: CREATING AND SUSTAINING CORPORATE VALUES
Chapter 5: MAXIM PHARMACEUTICALS (A): INTERNAL AND EXTERNAL DIALOGUES
Chapter 6: DIVERSA INC.: ETHICAL ISSUES IN BIOPROSPECTING PARTNERSHIPS
Chapter 7: PIPELINE BIOTECH A/S: COMPETING REGULATORY REGIMES FOR LABORATORY ANIMAL EXPERIMENTS
Chapter 8: TGN BIOTECH: A START-UP WITH ETHICAL ROOTS
Chapter 9: INTERLEUKIN GENETICS AND ALTICOR: AN UNLIKELY PARTNERSHIP
Chapter 10: SCIONA LTD.: A PIONEER IN NUTRIGENOMICS: THE PATH TO CONSUMER ACCEPTANCE
Chapter 11: AFFYMETRIX, INC.: USING CORPORATE ETHICS ADVICE
Chapter 12: PHARMASNPS INC.: CREATING AN ETHICS ADVISORY BOARD
Chapter 13: MONSANTO COMPANY: BIO-AGRICULTURE PIONEER
Chapter 14: NOVO NORDISK: THE TRIPLE BOTTOM LINE
Chapter 15: CONCLUSION: LESSONS FOR COMPANIES AND FUTURE ISSUES
INDEX
Recenzii
"Biotechnology
and
pharmaceutical
companies
are
often
driven
by
profit
goals,
but
the
case
studies
inBioindustry
Ethicsshow
that
this
is
increasingly
not
at
the
expense
of
ethical
integrity.
...lend[s]
important
insights
to
other
executives
and
professionals
who
might
be
developing
their
own
practices
and
policies."
- GENOMICS & PROTEOMICS (August 2005)
- GENOMICS & PROTEOMICS (August 2005)